BACKGROUND: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined the therapeutic effects and side effects of LDMC in a cohort of MBC patients. METHODS: Patients with MBC were included when LDMC with oral cyclophosphamide (CTX) and methotrexate (MTX) was administered between 2009 and 2015. The primary endpoint was disease control rate (DCR) ≥ 24 weeks after the start of LDMC. Secondary endpoints were duration of progression-free survival (PFS), rates of discontinuation due to side effects, and DCR with regard to subgroups. RESULTS: Retrospective data of 35 patients were available for this analysis. 31% patients achieved DCR. The median PFS was 12 weeks. 9% of patients discontinued LDMC due to adverse events. DCR was 37% in the first 2 lines and 25% in further lines of therapy. 22% of patients with multiple metastases and 35% with ≤2 different metastatic sites achieved DCR. DCR was achieved in 33% of hormone receptor(HR)-positive patients and 27% of HR-negative patients. CONCLUSION: The DCR of 31% is in line with the results of previous phase II studies. LDMC was well tolerated. Subgroup analysis was not able to identify a group in which LDMC was more efficient.
BACKGROUND: Low-dose metronomic chemotherapy (LDMC) is increasingly used in metastatic breast cancer (MBC). In this retrospective analysis, we examined the therapeutic effects and side effects of LDMC in a cohort of MBC patients. METHODS: Patients with MBC were included when LDMC with oral cyclophosphamide (CTX) and methotrexate (MTX) was administered between 2009 and 2015. The primary endpoint was disease control rate (DCR) ≥ 24 weeks after the start of LDMC. Secondary endpoints were duration of progression-free survival (PFS), rates of discontinuation due to side effects, and DCR with regard to subgroups. RESULTS: Retrospective data of 35 patients were available for this analysis. 31% patients achieved DCR. The median PFS was 12 weeks. 9% of patients discontinued LDMC due to adverse events. DCR was 37% in the first 2 lines and 25% in further lines of therapy. 22% of patients with multiple metastases and 35% with ≤2 different metastatic sites achieved DCR. DCR was achieved in 33% of hormone receptor(HR)-positive patients and 27% of HR-negative patients. CONCLUSION: The DCR of 31% is in line with the results of previous phase II studies. LDMC was well tolerated. Subgroup analysis was not able to identify a group in which LDMC was more efficient.
Authors: F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer Journal: Breast Date: 2016-12-05 Impact factor: 4.380
Authors: Nan Soon Wong; Robert A Buckman; Mark Clemons; Shailendra Verma; Susan Dent; Maureen E Trudeau; Kathie Roche; John Ebos; Robert Kerbel; Gerrit E Deboer; Donald J A Sutherland; Urban Emmenegger; Joyce Slingerland; Sandra Gardner; Kathleen I Pritchard Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: Erica L Mayer; Steven J Isakoff; Giannoula Klement; Sean R Downing; Wendy Y Chen; Keri Hannagan; Rebecca Gelman; Eric P Winer; Harold J Burstein Journal: Breast Cancer Res Treat Date: 2012-09-23 Impact factor: 4.872
Authors: M E Cazzaniga; L Cortesi; A Ferzi; L Scaltriti; F Cicchiello; M Ciccarese; S Della Torre; F Villa; M Giordano; C Verusio; M Nicolini; A R Gambaro; L Zanlorenzi; E Biraghi; L Legramandi; E Rulli Journal: Breast Cancer Res Treat Date: 2016-10-17 Impact factor: 4.872
Authors: Christoph Thomssen; Diana Lüftner; Michael Untch; Renate Haidinger; Rachel Würstlein; Nadia Harbeck; Doris Augustin; Susanne Briest; Johannes Ettl; Peter A Fasching; Frank Förster; Christian M Kurbacher; Hans-Joachim Lück; Norbert Marschner; Lothar Müller; Volkmar Müller; Lidia Perlova-Griff; Isabel Radke; Eugen Ruckhäberle; Iris Scheffen; Eva Schumacher-Wulf; Moritz Schwoerer; Dieter Steinfeld-Birg; Katja Ziegler-Löhr Journal: Breast Care (Basel) Date: 2020-02-10 Impact factor: 2.860
Authors: S Krajnak; C Schnatz; K Almstedt; W Brenner; F Haertner; A-S Heimes; A Lebrecht; G-M Makris; R Schwab; A Hasenburg; M Schmidt; M J Battista Journal: Breast Cancer Res Treat Date: 2020-06-03 Impact factor: 4.872
Authors: M E Cazzaniga; I Vallini; E Montagna; D Amoroso; R Berardi; A Butera; K Cagossi; L Cavanna; M Ciccarese; S Cinieri; E Cretella; E De Conciliis; A Febbraro; F Ferraù; A Ferzi; A Baldelli; A Fontana; A R Gambaro; O Garrone; V Gebbia; D Generali; L Gianni; F Giovanardi; A Grassadonia; V Leonardi; P Marchetti; S Sarti; A Musolino; M Nicolini; C Putzu; F Riccardi; D Santini; S Saracchini; M G Sarobba; M G Schintu; G Scognamiglio; P Spadaro; C Taverniti; D Toniolo; P Tralongo; A Turletti; R Valenza; M R Valerio; P Vici; P Di Mauro; V Cogliati; S Capici; L Clivio; V Torri Journal: Breast Cancer Res Treat Date: 2021-09-21 Impact factor: 4.872